{"id":"desmopressin-melt-formulation","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyponatremia (low sodium)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Facial flushing"}]},"_chembl":{"chemblId":"CHEMBL1200556","moleculeType":"Protein","molecularWeight":"1129.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Desmopressin mimics the action of endogenous antidiuretic hormone (ADH/vasopressin) by selectively activating V2 receptors in the renal collecting ducts, promoting aquaporin-2 water channel insertion and increasing water reabsorption. The MELT (melt) formulation is an orally disintegrating tablet that allows rapid absorption through the oral mucosa, providing faster onset compared to standard tablets. This formulation is particularly useful for conditions requiring rapid antidiuretic effect.","oneSentence":"Desmopressin is a synthetic vasopressin analog that binds to V2 receptors on kidney collecting duct cells to increase water reabsorption and reduce urine output.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:14.489Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Central diabetes insipidus"},{"name":"Nocturnal enuresis (bedwetting)"},{"name":"Polycystic kidney disease (off-label)"},{"name":"Von Willebrand disease and mild hemophilia A"}]},"trialDetails":[{"nctId":"NCT01036841","phase":"PHASE4","title":"Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2009-12","conditions":"Enuresis, Polyuria","enrollment":24},{"nctId":"NCT00615836","phase":"PHASE3","title":"An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (\"Melt\") Formulation of Desmopressin for the Treatment of Nocturia in Adults","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-12","conditions":"Nocturia","enrollment":554},{"nctId":"NCT00477490","phase":"PHASE3","title":"Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-05","conditions":"Nocturia","enrollment":799},{"nctId":"NCT01280188","phase":"PHASE3","title":"A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2011-01","conditions":"Central Diabetes Insipidus","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Minirin® Melt","Nocturin®","FE992026","Minirin"],"phase":"marketed","status":"active","brandName":"desmopressin MELT formulation","genericName":"desmopressin MELT formulation","companyName":"University Hospital, Ghent","companyId":"university-hospital-ghent","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Desmopressin is a synthetic vasopressin analog that binds to V2 receptors on kidney collecting duct cells to increase water reabsorption and reduce urine output. Used for Central diabetes insipidus, Nocturnal enuresis (bedwetting), Polycystic kidney disease (off-label).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}